Abstract | BACKGROUND/AIMS: METHODS: Mice were treated with intravenous CORM-2 (20 mg/kg body weight). Plasma 1,25(OH)2D3 and FGF23 concentrations were determined by ELISA, phosphate, calcium and creatinine concentrations by colorimetric methods, transcript levels by quantitative RT-PCR and protein expression by western blotting. Fgf23 mRNA transcript levels were further determined in rat osteosarcoma UMR106 cells without or with prior treatment for 24 hours with 20 µM CORM-2. RESULTS:
CORM-2 injection within 24 hours significantly increased FGF23 plasma levels and decreased 1,25(OH)2D3 plasma levels, renal Cyp27b1 gene expression as well as renal klotho protein abundance and transcript levels. Moreover, treatment of UMR106 cells with CORM-2 significantly increased Fgf23 transcript levels. CONCLUSION: CO-releasing molecule CORM-2 enhances FGF23 expression and release and decreases klotho expression and 1,25(OH)2D3 synthesis. © 2013 S. Karger AG, Basel.
|
Authors | Martina Feger, Abul Fajol, Aleksandra Lebedeva, Adrian Meissner, Diana Michael, Jakob Voelkl, Ioana Alesutan, Erwin Schleicher, Christoph Reichetzeder, Berthold Hocher, Syed M Qadri, Florian Lang |
Journal | Kidney & blood pressure research
(Kidney Blood Press Res)
Vol. 37
Issue 4-5
Pg. 496-505
( 2013)
ISSN: 1423-0143 [Electronic] Switzerland |
PMID | 24247848
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fgf23 protein, mouse
- Organometallic Compounds
- tricarbonyldichlororuthenium (II) dimer
- Cholecalciferol
- Fibroblast Growth Factor-23
- Carbon Monoxide
- Ruthenium
|
Topics |
- Animals
- Carbon Monoxide
(administration & dosage, blood)
- Cell Line, Tumor
- Cholecalciferol
(blood, metabolism)
- Female
- Fibroblast Growth Factor-23
- Injections, Intravenous
- Male
- Mice
- Mice, Inbred BALB C
- Organometallic Compounds
(administration & dosage)
- Rats
- Ruthenium
|